Pfizer completes acquisition of NextWave Pharmaceuticals

Download PDF Copy

Nov 29 2012

NewsGuard 100/100 Score

Pfizer Inc. (NYSE: PFE) today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

Upon the closing of the transaction, Pfizer now holds exclusive North American commercialization rights to Quillivant XR™ (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved in the U.S. for the treatment of ADHD. Quillivant XR received approval from the U.S. Food and Drug Administration on September 27, 2012, and is expected to be available in pharmacies in the U.S. in January 2013.

Source: Pfizer Inc.

Posted in: Business / Finance

Tags: Attention Deficit Hyperactivity Disorder (ADHD), Blood Pressure, Breast Milk, Breastfeeding, Depression, Food, Heart Rate, Hyperactivity, Methylphenidate, Nervous System, Pain, Pharmaceuticals, Psychiatry, Psychosis, Stroke

Comments (0)

Download PDF Copy

Suggested Reading

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

GLP-1 receptor agonists prove effective for kidney and cardiovascular outcomes

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Accelerating tobacco decline could boost global life expectancy

Accelerating tobacco decline could boost global life expectancy

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Early RSV vaccination in pregnancy provides best protection for newborns